Real-world experience of cannabidiol in conjunction with clobazam for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome: Results from a retrospective multicentre chart review in Germany
In this chart review of patients with severe treatment refractory LGS or DS receiving adjunctive CBD and CLB concomitantly, a reduction in seizure frequency and sustained treatment retention was observed for up to 12 months across age groups in real-world clinical practice. CBD discontinuations exclusively due to AEs were infrequent and the AE profile was generally aligned to that previously observed.
Authors
- Kerstin Alexandra Klotz (ORCID: https://orcid.org/0000-0002-1601-5384)
- Felix von Podewils (ORCID: https://orcid.org/0000-0002-3134-8697)
- Ilka Immisch
- Susanne Knake (ORCID: https://orcid.org/0000-0002-6298-0513)
- Susanne Schubert‐Bast (ORCID: https://orcid.org/0000-0003-1545-7364)
- Felix Rosenow
- Adam Strzelczyk (ORCID: https://orcid.org/0000-0001-6288-9915)
- Gerhard Kurlemann
- Elisa Buhleier
- Luise Herold
Institutions
- Goethe University Frankfurt (DE)
- Philipps University of Marburg (DE)
- Universitätsmedizin Greifswald (DE)
- University Medical Center Freiburg (DE)
- University Hospital Frankfurt (DE)
- Epilepsiezentrum Kleinwachau Gemeinnützige (DE)
- St. Bonifatius Hospital (DE)
Publication Details
- Journal
- Epilepsy & Behavior
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1016/j.yebeh.2025.110302
- Citations
- 7
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 10.30
Funders
- Jazz Pharmaceuticals
- GW Pharmaceuticals